Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06132685

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

Led by Emory University · Updated on 2026-02-10

200

Participants Needed

1

Research Sites

185 weeks

Total Duration

On this page

Sponsors

E

Emory University

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor. Steroids are the gold standard post-surgery treatment to reduce swelling (edema) at the surgical site to reduce neurological symptoms. Although, corticosteroids reduce edema, they have side effects including high blood sugar, high blood pressure, and can impair wound healing. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response. It also works to treat other conditions by reducing swelling and redness. Tapering doses dexamethasone may decrease steroid side effects without increasing the risk of edema in patients with brain tumors after a craniotomy.

CONDITIONS

Official Title

Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with radiographic findings consistent with high grade glioma, low grade glioma, meningioma, or brain metastasis
  • Age 18 years or older
Not Eligible

You will not qualify if you...

  • Known hypothalamic-pituitary-adrenal (HPA) axis dysfunction
  • Tumor causing compression of the sella or pituitary dysfunction
  • Known immunodeficiency including severe combined immunodeficiency, common variable immunodeficiency, or lymphocytopenia
  • Taking immunosuppressive drugs such as methotrexate, mycophenolate, rapamycin, tacrolimus, adalimumab, infliximab
  • More than two weeks of recent daily corticosteroid use or corticosteroids equivalent to over 85 mg dexamethasone in the last month
  • Current lymphoma or leukemia
  • History of solid organ transplant
  • Under 18 years old
  • Pregnant women
  • History of cerebrovascular accident causing neurologic deficit

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, United States, 30322

Actively Recruiting

Loading map...

Research Team

K

Kimberly Hoang, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here